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Abstract
Background: The presence of hypoxia in head and neck squamous cell carcinoma (HNSCC) is associated with
therapeutic resistance and increased risk of metastasis formation. αB-crystallin (HspB5) is a small heat shock protein,
which is also associated with metastasis formation in HNSCC. In this study, we investigated whether αB-crystallin
protein expression is increased in hypoxic areas of HNSCC biopsies and analyzed whether hypoxia induces αB-crystallin
expression in vitro and in this way may confer hypoxic cell survival.
Methods: In 38 HNSCC biopsies, the overlap between immunohistochemically stained αB-crystallin and
pimonidazole-adducts (hypoxiamarker) was determined. Moreover, expression levels of αB-crystallin were analyzed in
HNSCC cell lines under hypoxia and reoxygenation conditions and after exposure to reactive oxygen species (ROS)
and the ROS scavenger N-acetylcysteine (NAC). siRNA-mediated knockdown was used to determine the influence of
αB-crystallin on cell survival under hypoxic conditions.
Results: In all biopsies αB-crystallin was more abundantly present in hypoxic areas than in normoxic areas. Remarkably,
hypoxia decreased αB-crystallin mRNA expression in the HNSCC cell lines. Only after reoxygenation, a condition that
stimulates ROS formation, αB-crystallin expression was increased. αB-crystallin mRNA levels were also increased by
extracellular ROS, and NAC abolished the reoxygenation-induced αB-crystallin upregulation. Moreover, it was found that
decreased αB-crystallin levels reduced cell survival under hypoxic conditions.
Conclusions: We provide the first evidence that hypoxia stimulates upregulation of αB-crystallin in HNSCC. This
upregulation was not caused by the low oxygen pressure, but more likely by ROS formation. The higher expression of
αB-crystallin may lead to prolonged survival of these cells under hypoxic conditions.
Keywords: CRYAB protein, HspB5, Carcinoma, Squamous cell of head and neck, Hypoxia, Reactive oxygen species,
Hypoxic cell survival
Background
In solid tumors, hypoxic regions can be present when
cells are exposed to an oxygen pressure below 5 to
10 mmHg (0.66 – 1.32% O2) [1]. Hypoxia can be a result
of insufficient oxygen transportation to remote parts of a
tumor, caused by deficient blood vessel formation (chronic,
diffusion-limited hypoxia) or leaking or partially blockage
of blood vessels (acute, perfusion-limited hypoxia) [1].
Hypoxia might be intermittent when the blood flow is
restored after temporary vascular shutdown, which can
result in a cycling pattern of hypoxia and reoxygenation
[2-4]. The presence of hypoxic regions in the tumor is
detrimental for the patient, since hypoxic tumor cells are
associated with therapeutic resistance and metastatic
progression [5-7]. Despite the low oxygen levels, hypoxia is
also associated with the presence of reactive oxygen species
(ROS) [8-10]. As ROS are conventionally thought to
be cytotoxic and mutagenic, they could lead to cancer
progression and might be one of the reasons why the
presence of hypoxia is as a bad prognostic factor [11].
αB-crystallin is a small heat shock protein, which can
bind to partially unfolded proteins, thereby keeping
them in a soluble state to prevent their aggregation
[12,13]. It may protect cells from death induced by
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accumulation of unfolded proteins [14]. Furthermore,
αB-crystallin may confer stress resistance to cells by
inhibiting the processing of the pro-apoptotic protein
caspase-3 [15]. Besides being mainly expressed in eye
lens and muscle tissues [16], αB-crystallin can also be
found in several types of cancer, among which head and
neck squamous cell carcinoma (HNSCC) [17-19] and
breast carcinomas [20-22]. αB-crystallin expression is
associated with metastasis formation in HNSCC and in
breast carcinomas [19,23] and in other types of cancer,
expression is often correlated with poor prognosis as well
[12,13]. The expression of αB-crystallin can be increased
during various stresses, like heat shock, osmotic stress or
exposure to heavy metals [24]. Moreover, in tissues from
newborn piglets, αB-crystallin has been shown to be
upregulated by hypoxia [25,26]. In this study, we analyzed
whether the expression of αB-crystallin protein is affected
in hypoxic regions of HNSCC’s and whether αB-crystallin
knockdown influences cell survival under hypoxic stress.
Methods
Patients
Biopsy material of 38 HNSCC patients with stage II to
IV primary squamous cell carcinoma of the oral cavity,
oropharynx, hypopharynx or larynx was used (not all
biopsies of the available cohort could be used due to the
lack of material) [19,27]. Two hours before biopsies were
taken (1 per patient), patients received 500 mg/m2 body
surface of the hypoxia marker pimonidazole (intravenously,
dissolved in 100 ml 0.9% NaCl) over 20 minutes. The
obtained biopsies were snap-frozen and stored in liquid
nitrogen until immunohistochemical processing. Approval
from the ethics committee of Radboud University
Nijmegen Medical Centre was obtained and all patients
provided written informed consent.
Immunohistochemisty
Sections of the biopsies (5 μm) were mounted on
poly-L-lysine coated slides, fixed for 10 minutes in
acetone at 4°C and rehydrated in PBS. The sections
were incubated overnight at 4°C with 100-fold diluted
αB-crystallin antiserum [28] and subsequently incubated
for 30 minutes at 37°C with 600-fold diluted FabCy3 goat-
α-rabbit IgG (Jackson Immuno Research Laboratories Inc)
in PBS for 45 minutes at 37°C with 10-fold diluted
endothelium antibody PAL-E (Euro Diagnostica BV)
in Primary Antibody Diluent (PAD, Dako) and for
60 minutes at 37°C with 100-fold diluted Alexa 647
chicken-α-mouse IgG (Molecular probes) in PBS. For
visualization of the pimonidazole adducts, the sections were
stained with 1000-fold diluted rabbit-α-pimonidazole (gift
from Dr. James A. Raleigh, University of North Carolina),
diluted in PAD for 30 minutes at 37°C and subsequently
stained with 600-fold diluted Alexa 488 donkey-α-rabbit
IgG (Molecular probes) in PBS 30 minutes at 37°C.
During the latter step only the rabbit antibodies
directed to pimonidazole were stained [29]. Between the
incubations, 3 times 2 minutes washing steps in PBS were
performed. The sections were mounted using fluorostab
(ProGen Biotechnik GmbH).
Image acquisition
Scanning of the biopsy sections was performed with
a fluorescence microscope (Axioskop, Zeiss) and a
computer-controlled motorized stepping stage, using
IP-lab software (Scanalytics), as described previously [30].
Each section was completely sequentially scanned for
αB-crystallin, pimonidazole and blood vessel staining
at 100× magnification. The resulting composite grey
scale images were converted to binary images for further
analysis. Thresholds were set just above the background
staining for each individual staining. The total tumor
area was contoured manually, excluding nontumor
tissue, large necrotic areas and artifacts. The percentage of
αB-crystallin in the normoxic area was determined
as the pimonidazole-negative tumor area containing
αB-crystallin relative to the total pimonidazole-negative
tumor area. The percentage of αB-crystallin in the hypoxic
area was determined as the tumor area positive for
αB-crystallin and pimonidazole relative to the total
pimonidazole-positive area.
αB-crystallin mRNA expression upon hypoxia
The HNSCC cell line UT-SCC-5 (described in [31]), main-
tained in DMEM+GlutaMAX (Invitrogen) supplemented
with 10% fetal calf serum (Gibco-BRL) was seeded on
6-wells plates, 0.5×106 cells per well, N = 4 per time
point, and transferred after 24 hours from a standard
humidified 37°C incubator to a humidified 37°C H35
hypoxystation (Don Whitley Scientific) with 0.1% O2.
Samples were harvested after 0–22 hours of hypoxic
incubation for quantitative RNA analysis.
αB-Crystallin mRNA expression upon hypoxia,
reoxygenation and N-acetylcysteine
The HNSCC cell lines UT-SCC-5 and UT-SCC-15
(described in [31]), maintained in DMEM+GlutaMAX
supplemented with 10% fetal calf serum were seeded in
6-wells plates, 0.3×106 cells per well, N = 4 per condition,
and transferred after 24 hours from a standard humidified
37°C incubator to a H35 hypoxystation with 0.1% O2
(Don Whitley Scientific), or maintained in a standard
incubator. Normoxic and hypoxic samples were harvested
after 48 hours for quantitative RNA analysis. The re-
oxygenation samples were transferred after 24 hours
of hypoxic incubation to a standard incubator again
for 24 hours and subsequently harvested. To reduce
ROS, cells were incubated after 24 hours of hypoxia
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or normoxia with 0.05 mM NAC (Sigma). After NAC was
added, the reoxygenation samples were transferred
from the hypoxystation to a standard humidified 37°C
incubator and incubated for 24 hours and subsequently
harvested.
αB-crystallin protein expression upon hypoxia and
reoxygenation
The UT-SCC-5 cell line was seeded in T25 flasks,
0.9×106 cells per flask, N = 3 for the normoxic condition
and N = 4 for the hypoxic and reoxygenation condition,
and incubated for 5 hours in a standard humidified 37°C
incubator. The cells were transferred to the hypoxystation
maintained at 0.1% or kept in the standard incubator and
harvested after 48 hours. The reoxygenation samples were
transferred after 24 hours of hypoxic incubation to the
standard incubator again for 24 hours and subsequently
harvested. The cells were harvested in 2% sodium dodecyl
sulfate (Gibco), heated for 5 minutes at 100°C and
sonicated 5× 30 seconds on and 30 seconds off with
Bioruptor (Diagenode). The protein concentrations were de-
termined with BCA Protein Assay Kit (Thermo Scientific)
according to manufacturer’s protocol. Protein samples
(60 μg/sample) were separated by electrophoresis on a
12.5% polyacrylamide gel and transferred to a nitrocellulose
membrane (Protran). The membranes were blocked with
5% Elk (Campina) in PBS for an hour and washed 3 times
for 10 minutes with PBS + 0.0025% v/v Nonidet P-40. The
membranes were incubated for an hour with the 200-fold
diluted monoclonal mouse-α-human-αB-crystallin (RIKEN)
and 6000-fold diluted mouse-α-human-γ-tubulin as nce
(Sigma-Aldrich) diluted in 0.025% w/v Nonidet P-40 and
completed with 2% Elk in PBS. After washing, blots were
incubated for 1 hour with a 6000-fold dilution of IRDye
800CW goat-α-mouse IgG (LI-COR). The proteins were
visualized with the Odyssey scanner (LI-COR). Analysis was
performed using Odyssey 2.1 software.
αB-crystallin mRNA expression upon H2O2-induced
oxidative stress
UT-SCC-5 cells were seeded in 6-wells plates, 0.5×106
cells per well; N = 4 per concentration maintained in
DMEM+GlutaMAX supplemented with 10% fetal calf
serum. After 24 hours, cells were incubated with 0 mM
(mock), 0.3 mM, 1.5 mM or 3.0 mM H2O2 for 1 hour after
which they were incubated again in normal medium and
harvested after 7 hours for quantitative RNA analysis.
Hypoxia survival upon siRNA-mediated knock-down of
αB-crystallin
4.4 ×106 UT-SCC-5 cells were seeded in a T175 culture flask
and maintained in DMEM +GlutaMAX supplemented
with 10% fetal calf serum. After 24 hours, cells were
transfected with siRNA using Lipofectamine 2000
Reagent according to manufacturers’ protocol (Invitrogen).
The siRNA’swere directed against luciferase (siRNA
LUC, sequence: CGUACGCGGAAUACUUCGAdTdT)
and EGFP (si-EGFP, sequence: CGAGAAGCGCGAU
CACAUGdTdT) as negative controls and αB-crystallin
(si-αB1, sequence: GCACCCAGCUGGUUUGACAdTdT,
si-αB2 sequence: CCCUGAGUCCCUUCUACCUdTdT and
si-αB3, sequence: CCGGAUCCCAGCUGAUGUAdTdT).
After 5 hours, cells were reseeded 4.0×104 cells/well in
96-wells plates (6-fold per condition) and 1.25 ×105 cells/well
in 6-wells plates (4-fold per condition). The next day,
the cells in the 96-wells plates were washed twice with
PBS and DMEM (supplemented with GlutaMAX, 1 mM
sodiumpyruvate and 10% fetal calf serum) was added
containing 0 mM or 5 mM Glucose (Dextrose D(+),
Invitrogen). After one hour, cells were kept in the standard
incubator or transferred to the H35 hypoxystation main-
tained at 0.1% O2 and incubated for 24 hours. All 96-wells
plates were subsequently incubated in the standard
incubator for 3.5 hours and washed twice with PBS
and incubated for two hours in 10-fold diluted Cell
Counting Kit-8 solution (Sigma-Aldrich) in Optimem
(Invitrogen). The absorbance at 450 nm was measured
using an ELISA-reader (Tecan). The cells in the 6-wells
plates were harvested 48 hours after siRNA transfection
for quantitative RNA analysis to determine the efficiency
of αB-crystallin mRNA knockdown.
RNA analysis by quantitative RT-PCR
Total RNA from the harvested UT-SCC-5 and UT-SCC-15
cells was extracted using standard Trizol isolation. After
DNAse I treatment (Amplification grade, Invitrogen)
mRNAs were reverse transcribed using oligo (dT) primers
and the Reverse Transcription System (Promega) according
to manufacturer’s protocol starting with 1 μg of RNA in a
final volume of 20 μl. Subsequently, quantitative PCR
(qPCR) reactions were performed with 10 μl Power SYBR
Green (Applied BioSystems), 5 μM primers and 2 μl cDNA
in a final volume of 20 μl. The used primer sequences for
αB-crystallin are: ATCTTCTTTTGCGTCGCCAG and
TTCCCCATGGTGTCTGAGC, and for GAPDH: GATT
GAGGTGCATGGAAAAC and AGGACCCCATCAGAT
GACAG. The fluorescent signal intensities were recorded
with the ABI Prism 7000 system (Applied Biosystems).
Samples were kept for 10 minutes at 95°C, followed by
40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Data
analysis was performed on the CFX96 (Biorad). Analysis
was performed with CFX Manager Software (Biorad).
Statistics
Statistical analyses were performed using Graphpad Prism
5.00 software. Statistical analysis was performed using
One-way ANOVA and Tukey’s Multiple Comparison.
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Results
αB-crystallin protein is increased in the hypoxic areas of
HNSCC biopsies
The expression of αB-crystallin protein was analyzed in
the hypoxic and normoxic regions present in sections of
HNSCC biopsies of 38 different patients. To detect the
hypoxic regions, the hypoxia marker pimonidazole was
used. Figure 1 shows a representative binarized staining
of αB-crystallin and pimonidazole (Figure 1A and 1B).
Most of the hypoxic areas (Figure 1C, depicted in green)
are located in tumor areas at larger distance from blood
vessels (Figure 1C, depicted in blue). Interestingly, areas
showing αB-crystallin expression (Figure 1C, depicted in
red) are largely overlapping with hypoxic areas, though
αB-crystallin can be detected in normoxic areas as well.
By digital analysis of the scanned images the percentages
of αB-crystallin-positive areas in the normoxic tumor
areas and in the hypoxic tumor areas were determined for
each biopsy. In case hypoxia does not affect αB-crystallin
expression, the percentages of αB-crystallin-positive areas
present in normoxic and hypoxic areas would be similar
(Figure 2, grey line). However, as shown in Figure 2, the
percentages of αB-crystallin-positive areas were found to
be higher in the hypoxic than in the normoxic areas in all
analyzed HNSCC biopsies.
αB-crystallin expression is upregulated by reoxygenation,
not hypoxia
The increased presence of αB-crystallin in the hypoxic
areas might be the result of two different processes: a
stress-induced upregulation of αB-crystallin and/or a
longer survival of the cells expressing αB-crystallin. It
has been shown that hypoxia stimulates upregulation of
αB-crystallin in piglet stomach, colon and heart tissue
[25,26]. For this reason we first tested whether hypoxic
incubation is able to increase αB-crystallin mRNA
expression levels of HNSCC cell lines by using quantita-
tive RT-PCR. The HNSCC cell line UT-SCC-5 was
maintained for 22 hours under 0.1% O2 conditions
and every 2 hours (except t = 12 hours), αB-crystallin
mRNA expression levels were determined. Surprisingly,
αB-crystallin mRNA levels were found not to be upregu-
lated, but actually 2.3-fold downregulated after 22 hours
(Figure 3, P < 0.001), which suggests that the increased
expression of αB-crystallin in the hypoxic areas of HNSCC
is not directly caused by low oxygen levels. Reoxygenation
can also lead to αB-crystallin upregulation, as has been
shown in cultured optic nerve astrocytes [32]. Since
in some areas hypoxia can be intermittent, resulting in
periods with higher oxygen [2-4], we assessed the effect of
reoxygenation on αB-crystallin expression. Consistent
with the previous experiment, after 48 hours of hypoxic
incubation, αB-crystallin mRNA expression was down-
regulated in UT-SCC-5 as well as in the HNSCC cell
line UT-SCC-15 (Figure 4). However, upon reoxygenation,
αB-crystallin expression levels were significantly higher
than in the cells which were only incubated under
normoxic conditions. A similar response was also observed
in HeLa cells (data not shown), indicating that this might
be a general response.
Next we tested if a similar effect of the reoxygenation
could be found on the protein level. For this we could
only use the UT-SCC-5 cell line, since αB-crystallin
expression in UT-SCC-15 cells was too low to allow
detection by western blotting. After 48 hours of hypoxic
conditions, αB-crystallin protein levels were decreased
Figure 1 Immunofluorescent staining of human HNSCC for αB-crystallin, pimonidazole-modified proteins and PAL-E. Shown is a
representative biopsy section. The fluorescent grey scale images were binarized, resulting in black and white images for αB-crystallin staining
(A) and pimonidazole-modified proteins staining, indicating the hypoxic areas (B). The merged image with αB-crystallin staining (assigned red),
pimonidazole staining (assigned green) and PAL-E blood vessel staining (assigned blue) shows a substantial overlap between αB-crystallin and
hypoxic regions. Hypoxic regions are mostly located in areas at greater distance from vessels (C).
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2.0-fold (Figure 5, p < 0.001) and upon reoxygenation
the αB-crystallin level was raised 1.5-fold compared
to the hypoxic level (p < 0.01). Although the level
after reoxygenation did not reach the level observed
at normoxic conditions (p < 0.01), these results show
that also the αB-crystallin protein was upregulated
upon reoxygenation after hypoxia.
αB-crystallin mRNA overexpression during reoxygenation
is induced by ROS
Reoxygenation stimulates the production of ROS [33],
which at a high concentration is stressful for cells. As a
reaction, cells can protect themselves by increasing the
level of stress proteins [32]. To test whether ROS induces
αB-crystallin expression in HNSCC cells, UT-SCC-5 cells
were treated with H2O2. The cells were incubated for
1 hour with a H2O2 concentration series between 0 and
3.0 mM H2O2 and subsequently harvested after 7 hours
(Figure 6). At the protein level no effect could be detected,
because the protein expression was too low to allow
accurate measurement by western blotting (data not shown).
However, a significant increase in αB-crystallin mRNA
expression could be observed at 1.5 mM and 3.0 mM
H2O2, compared to incubation with mock (P < 0.001).
Figure 2 αB-crystallin expression is increased in hypoxic areas.
The symbols represent the relative amount of αB-crystallin staining
in the normoxic areas and in the hypoxic areas for each individual
HNSCC. Equal staining of αB-crystallin in the normoxic and hypoxic
areas would be according to the grey line.
Figure 3 Relative αB-crystallin mRNA expression during hypoxia.
αB-crystallin mRNA expression levels in UT-SCC-5 cells after incubation
in a humidified 37CH35 hypoxystation at 0.1% O2 for the indicated
time points. αB-crystallin mRNA expression levels were assessed via
RT-qPCR (N = 4) *** p < 0.001, ** 0.001 < p < 0.01.
Figure 4 Relative αB-crystallin mRNA levels after hypoxia and
reoxygenation. αB-crystallin mRNA levels in UT-SCC-5 and UT-SCC-15
cells under 48 hours normoxia (N), hypoxia (H, 0.1% O2) and after
reoxygenation (R, 24 hours 0.1% O2/24 hours normoxia). αB-crystallin
mRNA expression levels were assessed via RT-qPCR (N = 4). *** p < 0.001,
** 0.001 < p< 0.01, * 0.01 < p < 0.05.
Figure 5 Relative αB-crystallin protein levels after hypoxia and
reoxygenation. αB-crystallin protein expression levels in UT-SCC-5
cells under 48 hours normoxia (N), hypoxia (H, 0.1% O2) and after
reoxygenation (R, 24 hours 0.1% O2/24 hours normoxia). αB-crystallin
protein expression was analyzed of 3–4 independent incubations via
western blotting (A) and quantified (B). ***p < 0.001, ** 0.001 < p < 0.01.
van de Schootbrugge et al. BMC Cancer 2014, 14:252 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/252
Next, it was tested whether induction of αB-crystallin
upon reoxygenation can be reduced with the ROS
scavenger NAC. UT-SCC-5 cells were incubated with-
out and with NAC during normoxia, hypoxia and reoxy-
genation. Without NAC, αB-crystallin mRNA levels were
again downregulated during hypoxia and upregulated dur-
ing reoxygenation, as expected (Figure 7). In the presence
of NAC, the hypoxia-induced αB-crystallin mRNA down-
regulation remained the same, whilst the upregulation upon
reoxygenation was reduced 1.7-fold, compared to reoxygen-
ation without NAC. These results suggest that the ROS
produced upon reoxygenation is at least in part responsible
for the upregulation of αB-crystallin in UT-SCC-5 cells.
αB-crystallin knockdown leads to diminished cell survival
under hypoxic and hypoglycemic stress
Next, it was investigated whether cells expressing
αB-crystallin were able to survive longer under hypoxic
conditions. In hypoxic areas, not only a shortage in oxygen,
but hypoglycemia as well is a physiological stressor
[34]. Since glucose is able to protect cells under hypoxic
conditions [35] and glucose is the main energy source
required for HNSCC cell survival [36,37], medium
without glucose was used as an additional stress condition.
Reduction of αB-crystallin expression in UT-SCC-5 cells
was obtained by siRNA-mediated knockdown. Cells with
normal and reduced levels of αB-crystallin were exposed
to a hypoxic oxygen level of 0.1% for 24 hours, after which
the survival was determined by analyzing the cell number
with Cell Counting Kit-8. The knockdown of αB-crystallin
was performed with 3 different siRNAs and compared
with 2 different control siRNAs (Figure 8A). Under
normoxic conditions in the presence of 5 mM glucose,
knockdown of αB-crystallin did not significantly alter cell
survival, although with all three siRNAs a trend in survival
reduction was observed (Figure 8B). Hypoxic stress in the
presence of 5 mM glucose, led to a significant lower cell
survival, compared to normoxic conditions (67% for
siEGFP and siLUC). Cell survival could be further reduced
significantly, by knockdown of αB-crystallin (57% for si-
αB1 and 58% for si-αB2 and si-αB3). Under normoxic
conditions, 0 mM glucose led to lower cell survival rates
(66% for siEGFP and 63% for si-LUC), which was further
reduced as well after knockdown of αB-crystallin (57% for
si-αB1 and 55% for si-αB2 and si-αB3). Combining hypoxic
as well as hypoglycemia stress was detrimental resulting in
0% cell survival. Since all 3 different αB-crystallin siRNAs
gave similar results, it is very unlikely that these observa-
tions are due to off-targets effects. These results show that
reduction of the αB-crystallin level decreases the survival of
hypoxia-exposed and glucose-deprived cells.
Discussion
In the current study, we show that more αB-crystallin
protein is present in hypoxic HNSCC tumor areas than
in normoxic areas. Since an increased αB-crystallin
expression might be the result of a stress-induced
transcriptional upregulation, we investigated whether
hypoxic stress is able to induce αB-crystallin expression in
HNSCC cell lines. Remarkably, under hypoxic conditions
αB-crystallin mRNA expression was found to be downregu-
lated in UT-SCC-5 and UT-SCC-15 cells. It is not clear
how αB-crystallin is downregulated, but this could be due
to a general transcription shutdown caused by epigenetic
modifications [38,39]. Only after reoxygenation, a signifi-
cant upregulation of αB-crystallin mRNA in the HNSCC
cell lines was found. The same trend was observed at the
protein level. The upregulation of αB-crystallin has also
Figure 6 Relative αB-crystallin mRNA levels upon H2O2-incubation.
Relative αB-crystallin mRNA levels in UT-SCC-5 cells after incubation with
0.0 mM (mock), 0.3 mM, 1.5 mM or 3.0 mM H2O2 for 1 hour and 7 hours
of recovery. αB-crystallin mRNA expression levels were assessed via
RT-qPCR (N = 4). *** p < 0.001.
Figure 7 Effect of the ROS-scavenger NAC on αB-crystallin mRNA
levels during reoxygenation. UT-SCC-5 cells after incubation with
mock or NAC under 48 hours normoxia (N), hypoxia (H, 0.1% O2) and
after reoxygenation (R, 24 hours 0.1% O2/24 hours normoxia).
** 0.001 < p < 0.01, * 0.01 < p < 0.05.
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been observed in other cell types and by different forms of
reoxygenation stress, such as chemical ischemic/recovery
stress and ischemic/reperfusion injury [40,41], although
from those studies it appeared that the upregulation
of αB-crystallin is not a general mechanism since not
all cell types show this effect [40]. The reoxygenation-
induced upregulation of αB-crystallin also fits with the
studies performed with the piglets, where hypoxia-induced
αB-crystallin upregulation was detected [25,26]. In these
studies piglets were maintained in a hypoxic chamber for
either 1 or 4 hours and were allowed to recover over
periods of 1 to 68 hours under normoxic condition
and thus underwent a period of reoxygenation.
The reoxygenation-induced upregulation of αB-crystallin
mRNA is at least partially caused by ROS, based on the
inhibitory effect of the ROS-scavenger NAC (Figure 7).
Despite the low level of oxygen, significant levels of
ROS can be present in hypoxic areas and thus can be
responsible for the induction of αB-crystallin expression.
ROS-levels in hypoxic areas can be increased by moments
of reoxygenation due to intermittent, perfusion-limited
hypoxia [9] or produced by necrotic cells which are often
present in hypoxic tumor areas [34,42-44]. Also ROS can
be produced by a synergistic effect of oncogenic-induced
stimulation of increased mitochondrial capacity and
low oxygen levels, which causes an ineffective functioning
of mitochondrial respiratory complexes [10]. For this a
hypoxia-induced downregulation of thioredoxin reductase
1 seems to be important in maintaining high levels of
ROS under hypoxic conditions [45]. As mentioned earlier,
some normoxic areas may also contain significant levels of
αB-crystallin. These local αB-crystallin expressions might
be explained by intermittent hypoxia as well. As shown by
Bennewith and colleagues a substantial proportion of
tumor cells can go through cycles of hypoxia and normoxia
[46,47]. If the intervals of hypoxia are too short or if pimo-
nidazole is not present at the hypoxic moments, errone-
ously no staining by this marker will be detected [46,47].
Nevertheless, αB-crystallin induced by the ROS formed
during the reoxygenation periods might still be present.
αB-crystallin is a stress protein which may enhance cell
survival upon ROS exposure, as shown for H2O2 treated
mouse retinal pigment epithelium cells [48]. Based on
knockdown experiments, we showed that αB-crystallin is
able to play a role in the survival of cells coping with
hypoxia and glucose-deprivation stress as well. It is
thus possible that the αB-crystallin present in hypoxic
tumor areas plays a role in tumor cell survival during
Figure 8 Knockdown of αB-crystallin expression reduces hypoxia and hypoglycemia survival. Expression of αB-crystallin mRNA in
UT-SCC-5 cells was reduced by three different αB-crystallin siRNAs (αB1, αB2 and αB3). LUC and EGFP were used as negative control siRNAs
(A). Survival of siRNA-treated UT-SCC-5 cells under normoxic (N) and hypoxic (H, 0.1% O2 for 24 hours) conditions in the presence of 5 mM or
0 mM glucose (B). Cell survival was assessed via a colorimetric assay using cell counting kit-8. The optical density (O.D.) of siEGFP-treated cells
was set at 100%. *** p < 0.001, ** 0.001 < p < 0.01, * 0.01 < p < 0.05.
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hypoxic stress [34,49]. This protective activity of αB-
crystallin may further increase the number of αB-crystallin-
positive cells in hypoxic tumor areas. In summary, the rela-
tive higher levels of αB-crystallin in HNSCC hypoxic tumor
areas might be caused by a combination of ROS-induced
αB-crystallin upregulation and an enhanced survival
of αB-crystallin-positive cells exposed to this stress.
The enhanced expression of αB-crystallin in HNSCC
may have a negative effect on the prognosis of the
patient. We have recently found that αB-crystallin
expression is associated with distant metastases formation
in HNSCC patients [19]. This association might relate to
the chaperone function of αB-crystallin in mediating
folding and secretion of VEGF. αB-crystallin is able to
bind misfolded vascular endothelial growth factor
(VEGF), leading to enhanced VEGF secretion [50,51].
VEGF is specifically upregulated by hypoxia-inducible fac-
tor 1 (HIF1) and is important for tumor vascularization.
VEGF induction is thus a mechanism to alleviate hypoxic
circumstances [52,53]. Cycling hypoxia-induced VEGF
expression has been shown to increase pulmonary
metastasis formation in mice [54]. Since αB-crystallin can
increase hypoxic cell survival and can help in the (re)folding
of hypoxia-induced VEGF expression, αB-crystallin
expression could ultimately increase the risk of hypoxic
tumors to become metastasis-prone [55]. Furthermore, by
increasing hypoxic cell survival αB-crystallin may also
decrease the sensitivity of a tumor to cancer treatments,
such as radiation or other cancer treatments, as shown by
the effect of αB-crystallin on tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) as well as cisplatin-
induced apoptosis in human ovarian cancer cells [56].
Because of its potential to interfere with anti-tumor
therapies, αB-crystallin might be a promising target for
anti-cancer treatment.
Conclusions
Enhanced αB-crystallin expression in HNSCC and also in
other kind of tumors correlates with poor prognosis of the
patients. The underlying stress that induces αB-crystallin
expression in HNSCC was not known. Here we show that
αB-crystallin is most abundantly present in the hypoxic
areas of the tumor, likely caused by ROS stress. The
increased expression of αB-crystallin may lead to prolonged
survival of hypoxic cells, thereby protecting those cells
which are most resistant against cancer treatments.
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